Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Targeted Therapies for the Treatment of Glioblastoma in Adults.

Chuang DF, Lin X.

Curr Oncol Rep. 2019 May 17;21(7):61. doi: 10.1007/s11912-019-0807-1. Review.

PMID:
31102038
2.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

3.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

4.

Molecularly targeted therapies for recurrent glioblastoma: current and future targets.

Lau D, Magill ST, Aghi MK.

Neurosurg Focus. 2014 Dec;37(6):E15. doi: 10.3171/2014.9.FOCUS14519. Review.

5.

Immunotherapy for glioblastoma: concepts and challenges.

Weiss T, Weller M, Roth P.

Curr Opin Neurol. 2015 Dec;28(6):639-46. doi: 10.1097/WCO.0000000000000249. Review.

6.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
7.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

8.

Current and emerging EGFR therapies for glioblastoma.

Artene SA, Tuţă C, Dragoi A, Alexandru O, Stefana Oana P, Tache DE, Dănciulescu MM, Boldeanu MV, Siloşi CA, Dricu A.

J Immunoassay Immunochem. 2018;39(1):1-11. doi: 10.1080/15321819.2017.1411816. Epub 2018 Feb 2. Review.

PMID:
29308973
9.

Glioblastoma targeted therapy: updated approaches from recent biological insights.

Touat M, Idbaih A, Sanson M, Ligon KL.

Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106. Review.

10.

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Chan KK, Glenny AM, Weldon JC, Furness S, Worthington HV, Wakeford H.

Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010341. doi: 10.1002/14651858.CD010341.pub2. Review.

PMID:
26625332
11.

Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH.

Nat Rev Neurol. 2015 Sep;11(9):504-14. doi: 10.1038/nrneurol.2015.139. Epub 2015 Aug 11. Review.

12.

New Approaches for Immune Directed Treatment for Ovarian Cancer.

Hardwick N, Frankel PH, Cristea M.

Curr Treat Options Oncol. 2016 Mar;17(3):14. doi: 10.1007/s11864-016-0389-1. Review.

PMID:
26942589
13.

Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.

Sengupta S, Thaci B, Crawford AC, Sampath P.

Biomed Res Int. 2014;2014:952128. doi: 10.1155/2014/952128. Epub 2014 Aug 27. Review.

14.

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, Dhermain F.

Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Review. French.

PMID:
27032303
15.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

16.

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.

Goss GD, Spaans JN.

Oncologist. 2016 Feb;21(2):205-13. doi: 10.1634/theoncologist.2015-0209. Epub 2016 Jan 14. Review.

17.

The promises of immunotherapy in gliomas.

Mildenberger I, Bunse L, Ochs K, Platten M.

Curr Opin Neurol. 2017 Dec;30(6):650-658. doi: 10.1097/WCO.0000000000000491. Review.

PMID:
28984704
18.

Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.

Mosquera C, Maglic D, Zervos EE.

Cancer Genet. 2016 Dec;209(12):567-581. doi: 10.1016/j.cancergen.2016.07.003. Epub 2016 Aug 2. Review.

PMID:
27613577
19.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

20.

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Spigel DR, Socinski MA.

J Thorac Oncol. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88. Review.

Supplemental Content

Support Center